NGHIÊN CỨU NỒNG ĐỘ PCSK9 HUYẾT TƯƠNG Ở BỆNH NHÂN UNG THƯ BIỂU MÔ TẾ BÀO GAN

Abstract

Objective: To investigate the relationship of plasma Proprotein convertase subtilisin/kexin type 9 (PCSK9) level with paraclinical characteristics in hepatocellular carcinoma patients and initial find out plasma PCSK9 level in prediction hepatocellular carcinoma. Subjects and methods: Prospective, cross-sectional description of 60 hepatocellular carcinoma patients at the Gastroenterology Department - Military Hospital 103 and 60 control subjects. PCSK9 concentration in plasma was determined by Enzyme-Linked ImmunoSorbent Assay (ELISA). Results: Plasma PCSK9 levels were significantly positive correlated to platelets (correlation coefficient r = 0,5, p < 0,05). Median plasma PCSK9 levels (172,9 ng/mL) in patients with hepatocellular carcinoma was significantly higher than that in control group (135,5 ng/mL), p < 0,001. PCSK9 predicted hepatocellular carcinoma at a moderate level with AUC of 0,70 (95% CI: 0,61-0,79). At the cut-off value of 151,95 ng/mL, PCSK9 had 68,3% sensitivity, 65,0% specificity for predicting hepatocellular carcinoma. Conclusion: Plasma PCSK9 level had the relationship with platelets in hepatocellular carcinoma patients. PCSK9 was a useful biomarker in diagnosis of  hepatocellular carcinoma.